Overview

Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Carboplatin
Docetaxel
Pemetrexed